Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Far from MCAR: obtaining population-level estimates of HIV viral suppression

View ORCID ProfileLaura B. Balzer, James Ayieko, Dalsone Kwarisiima, Gabriel Chamie, Edwin D. Charlebois, Joshua Schwab, Mark J. van der Laan, Moses R. Kamya, Diane V. Havlir, Maya L. Petersen
doi: https://doi.org/10.1101/19012781
Laura B. Balzer
1Department of Biostatistics and Epidemiology, School of Public Health and Health Sciences, University of Massachusetts, Amherst, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Laura B. Balzer
  • For correspondence: lbalzer@umass.edu
James Ayieko
2Kenya Medical Research Institute, Center for Microbiology Research, Nairobi, Kenya
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dalsone Kwarisiima
3Infectious Diseases Research Collaboration, Kampala, Uganda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabriel Chamie
4Division of HIV, Infectious Diseases and Global Medicine, Department of Medicine, University of California, San Francisco, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edwin D. Charlebois
5Division of Prevention Science, Department of Medicine, University of California, San Francisco, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joshua Schwab
6Division of Biostatistics, School of Public Health, University of California, Berkeley, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark J. van der Laan
6Division of Biostatistics, School of Public Health, University of California, Berkeley, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Moses R. Kamya
7School of Medicine, Makerere University, Kampala, Uganda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Diane V. Havlir
4Division of HIV, Infectious Diseases and Global Medicine, Department of Medicine, University of California, San Francisco, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maya L. Petersen
6Division of Biostatistics, School of Public Health, University of California, Berkeley, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Population-level estimates of disease prevalence and control are needed to assess the effectiveness of prevention and treatment strategies. However, available data are often subject to differential missingness. Consider population-level HIV viral suppression: proportion of all HIV-positive persons who are suppressing viral replication. Individuals with measured HIV status, and, among HIV-positive individuals, those with measured viral suppression are likely to differ from those without such measurements.

Methods We discuss three sets of assumptions sufficient to identify population-level suppression over time in the intervention arm of the SEARCH Study (NCT01864603), a community randomized trial in rural Kenya and Uganda (2013-2017). Using data on nearly 100,000 participants, we compare estimates from an unadjusted approach assuming data are missing-completely-at-random (MCAR); stratification on age group, sex, and community; and, targeted maximum likelihood estimation (TMLE) with Super Learner to adjust for baseline and time-updated predictors of measurement.

Results Despite high annual coverage of testing, estimates of population-level viral suppression varied by identification assumption. Unadjusted estimates were most optimistic: 50% of HIV-positive persons suppressed at baseline, 80% at Year 1, 85% at Year 2, and 85% at Year 3. Stratification on baseline predictors yielded slightly lower estimates, and full adjustment reduced estimates further: 42% of HIV-positive persons suppressed at baseline, 71% at Year 1, 76% at Year 2, and 79% at Year 3.

Conclusions Estimation of population-level disease burden and treatment coverage require appropriate adjustment for missingness. Even in “Big Data” settings, estimates relying on the MCAR assumption or baseline stratification should be interpreted with caution.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT01864603

Funding Statement

This work was supported by grant numbers U01AI099959, UM1AI068636, and R01AI074345-06A1 from National Institute of Allergy and Infectious Diseases at the National Institutes of Health; by the President’s Emergency Plan for AIDS Relief; and by Gilead Sciences, which provided Truvada®.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Conflicts of Interest: There is no conflict of interest

  • Sources of Funding: This work was supported by grant numbers U01AI099959, UM1AI068636, and R01AI074345-06A1 from National Institute of Allergy and Infectious Diseases at the National Institutes of Health; by the President’s Emergency Plan for AIDS Relief; and by Gilead Sciences, which provided Truvada®.

  • Computing code: Will be made available on GitHub

  • Data availability: Data sufficient to reproduce the study findings will be made available approximately one year after completion of the ongoing trial (NCT01864603). Further inquiries can be directed to the SEARCH Scientific Committee at douglas.black{at}uscf.edu.

Data Availability

Data sufficient to reproduce the study findings will be made available approximately one year after completion of the ongoing trial (NCT01864603). Further inquiries can be directed to the SEARCH Scientific Committee at douglas.black{at}uscf.edu.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted November 22, 2019.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Far from MCAR: obtaining population-level estimates of HIV viral suppression
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Far from MCAR: obtaining population-level estimates of HIV viral suppression
Laura B. Balzer, James Ayieko, Dalsone Kwarisiima, Gabriel Chamie, Edwin D. Charlebois, Joshua Schwab, Mark J. van der Laan, Moses R. Kamya, Diane V. Havlir, Maya L. Petersen
medRxiv 19012781; doi: https://doi.org/10.1101/19012781
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Far from MCAR: obtaining population-level estimates of HIV viral suppression
Laura B. Balzer, James Ayieko, Dalsone Kwarisiima, Gabriel Chamie, Edwin D. Charlebois, Joshua Schwab, Mark J. van der Laan, Moses R. Kamya, Diane V. Havlir, Maya L. Petersen
medRxiv 19012781; doi: https://doi.org/10.1101/19012781

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (46)
  • Cardiovascular Medicine (412)
  • Dentistry and Oral Medicine (69)
  • Dermatology (47)
  • Emergency Medicine (142)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4843)
  • Forensic Medicine (3)
  • Gastroenterology (183)
  • Genetic and Genomic Medicine (674)
  • Geriatric Medicine (70)
  • Health Economics (192)
  • Health Informatics (626)
  • Health Policy (318)
  • Health Systems and Quality Improvement (203)
  • Hematology (85)
  • HIV/AIDS (156)
  • Infectious Diseases (except HIV/AIDS) (5326)
  • Intensive Care and Critical Care Medicine (328)
  • Medical Education (93)
  • Medical Ethics (25)
  • Nephrology (75)
  • Neurology (685)
  • Nursing (42)
  • Nutrition (114)
  • Obstetrics and Gynecology (126)
  • Occupational and Environmental Health (205)
  • Oncology (439)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (89)
  • Pain Medicine (35)
  • Palliative Medicine (16)
  • Pathology (129)
  • Pediatrics (194)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (778)
  • Public and Global Health (1810)
  • Radiology and Imaging (323)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (62)
  • Surgery (100)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (37)